Psychiatric NP Scope of Practice for Weight Loss/GLP-1 in Texas

You spent years training to treat psychiatric conditions — not metabolic disorders. But now patients are asking about Ozempic for antipsychotic-induced weight gain, or you’re seeing telehealth weight-loss services advertise six-figure incomes and wondering if it’s a legitimate expansion opportunity.

Here’s the reality: Yes, psychiatrists can legally prescribe weight-loss medications, including GLP-1 agonists and appetite suppressants, via telehealth in most states. But the regulatory maze is brutal — DEA rules are in flux through 2026, state medical boards impose wildly different standards (Florida requires quarterly follow-ups and written consent; New York mandates in-person visits for controlled substances), and scope-of-practice lines blur when a psychiatrist ventures into obesity medicine.

This guide cuts through the confusion. We’ll cover what’s actually legal right now, which medications trigger DEA restrictions, how state rules differ for psychiatrists versus PMHNPs, and what compliance looks like if you want to add weight management to your practice — or join a telehealth platform doing it at scale.

The DEA Situation: Temporary Extension Through 2026, Then Unknown

Federal law normally requires an in-person exam before prescribing controlled substances via telehealth. This comes from the 2008 Ryan Haight Act, designed to stop internet pill mills. Pre-COVID, if you wanted to prescribe phentermine (a Schedule IV appetite suppressant) to a new patient remotely, you couldn’t — federal law required at least one face-to-face visit first.

The pandemic changed that. HHS and DEA waived the in-person requirement, enabling telehealth prescribing of controlled substances (ADHD stimulants, anxiety meds, weight-loss drugs) without ever meeting patients physically.

As of January 2026, that flexibility is extended through December 31, 2026. DEA and HHS announced the fourth temporary extension to avoid a ‘telehealth cliff’ while they finalize permanent rules. Translation: you can continue prescribing controlled weight-loss medications (like phentermine) via telehealth to new patients through the end of 2026, federally.

What happens in 2027 is anyone’s guess. DEA proposed rules in January 2025 that would create a ‘Special Registration’ pathway for telemedicine providers to prescribe Schedule III–V drugs remotely, and potentially allow Schedule II prescribing (like Adderall) for specific specialties under restrictions — but these rules aren’t finalized. The reality: DEA has been promising ‘permanent telemedicine rules’ since 2022, and we’re still operating on temporary waivers.

For weight-loss prescribing specifically: Most obesity medications fall outside DEA jurisdiction entirely. Semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda) — the blockbuster GLP-1 agonists — are not controlled substances. You can prescribe them via telehealth with zero DEA restrictions, as long as you meet standard prescribing requirements and state telehealth laws.

Phentermine (Adipex-P, Lomaira) is Schedule IV controlled — covered by the DEA extension now, but potentially subject to in-person requirements post-2026. Phentermine/topiramate (Qsymia) is also controlled (Schedule IV). The older amphetamine-based appetite suppressants (like Benzphetamine, Schedule III) rarely get prescribed anymore due to abuse potential and better alternatives.

Bottom line: If you’re prescribing GLP-1s for weight loss via telehealth, DEA rules don’t apply. If you’re prescribing phentermine, you’re good through 2026 federally — but watch for state overrides (more below) and prepare for potential policy changes in 2027.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State Law Overrides: Where In-Person Requirements Still Exist

Federal DEA waivers don’t override stricter state laws. Some states maintained or reinstated in-person exam requirements for controlled substances even during the federal flexibility period.

New York is the strictest. As of May 2025, New York regulations (10 NYCRR §80.63) require at least one in-person medical evaluation before prescribing any controlled substance to a patient via telehealth. Limited exceptions exist — if another NY provider saw the patient in person within the last 12 months and shared records, or if you’re covering for a colleague’s established patient, or in emergencies (5-day supply max) — but for typical telehealth weight-loss prescribing, you cannot start phentermine without seeing the patient face-to-face in New York.

This applies to psychiatrists prescribing stimulants for ADHD too. New York essentially said ‘we don’t care what DEA allows federally — our state requires in-person for controlled substances.’ It’s a patient safety stance after years of pill mill crackdowns.

For non-controlled weight-loss meds (GLP-1s), New York has no in-person requirement — standard telehealth evaluation via video is fine.

Florida takes a different approach: Florida’s telehealth law prohibits prescribing Schedule II controlled substances via telehealth except for psychiatric treatment, inpatient/hospice care, and nursing home patients. Since phentermine is Schedule IV (not Schedule II), Florida allows telehealth prescribing of phentermine for weight loss — no in-person exam required by state law.

However, Florida imposes specialty-specific obesity treatment rules (more below): quarterly follow-ups, written informed consent, BMI documentation. These apply regardless of telehealth vs in-person.

California, Texas, Pennsylvania, Illinois: No state-level in-person requirements for controlled substance prescribing via telehealth currently. These states defer to federal DEA rules (meaning the 2026 extension applies). California explicitly allows telehealth to satisfy the ‘appropriate prior examination’ standard for prescribing. Texas reformed its telehealth law in 2017 to remove in-person mandates. Illinois and Pennsylvania follow federal guidance.

Practical takeaway: If you’re in New York or prescribing to New York patients, you need an in-person visit (or coordinating referral) before starting controlled weight-loss meds. Everywhere else, the DEA extension covers you federally through 2026 — but always verify current state law, because boards can change rules quickly.

Psychiatrist Scope of Practice: Can You Legally Prescribe for Obesity?

Short answer: Yes, you can. A fully licensed physician (MD/DO) psychiatrist has unrestricted prescriptive authority. There’s no law saying ‘only endocrinologists or bariatric specialists can prescribe weight-loss medications.’ Scope of practice isn’t defined by specialty for physicians — it’s defined by competence and standard of care.

You can prescribe metformin for prediabetes, statins for cholesterol, GLP-1s for weight loss — legally, you’re allowed. The question is whether you should, and whether you can meet the expected standard of care.

Medical boards will hold you to the same expectations as any physician treating obesity. That means:

• Proper evaluation: Documented BMI calculation, assessment of comorbidities (diabetes, hypertension, sleep apnea), ruling out secondary causes of obesity (hypothyroidism, Cushing’s), evaluating contraindications to specific medications
• Informed consent: Discussing risks, benefits, alternative treatments (diet, exercise, bariatric surgery), setting realistic expectations
• Monitoring: Regular follow-ups to assess efficacy, side effects, weight trajectory — not just writing a prescription and disappearing
• Coordination of care: Communicating with the patient’s primary care provider, especially for patients with complex medical histories

Some states codify these expectations. Florida’s Board of Medicine rule (64B8-9.012) requires any physician prescribing weight-loss medications to:

• Document patient’s BMI ≥30 (or ≥27 with comorbidities) or body fat percentage exceeding gender-specific thresholds
• Obtain written informed consent outlining risks of the medication
• Re-evaluate the patient at least every 3 months while on treatment
• Provide or refer for nutritional and exercise counseling

This applies to psychiatrists just like internists. If you’re prescribing Wegovy to a patient via telehealth in Florida, you need quarterly video visits documented, consent forms signed, notes showing you discussed lifestyle modification.

New Jersey takes it further — their regulations require prescribers to conduct a comprehensive history and physical, rule out endocrine causes of obesity, assess psychological factors (eating disorders, depression), and provide documented nutrition/exercise counseling before prescribing weight-loss drugs. They also mandate psychiatric evaluation and treatment if needed before or concurrent with weight-loss medication.

This is actually where psychiatrists have an advantage — you’re already trained to assess binge-eating disorder, depression contributing to weight gain, medication-induced metabolic issues. The New Jersey rule essentially says ‘don’t just throw pills at obesity; address the whole patient,’ which aligns with psychiatric practice.

Where psychiatrists get into trouble: Treating obesity as a side hustle without proper infrastructure. If you’re prescribing semaglutide but not monitoring weight, blood pressure, lipids, or coordinating with endocrinology when patients develop gallstones or pancreatitis — that’s outside standard of care, and medical boards will discipline you the same as any other specialist practicing beyond their competence.

Many psychiatrists handle this by collaboration: prescribing GLP-1s for antipsychotic-induced weight gain in consultation with the patient’s PCP, or joining a telehealth platform that provides the clinical infrastructure (dietitians, endocrine backup, monitoring protocols) rather than going solo.

Some pursue additional training — the American Board of Obesity Medicine offers certification (ABOM Diplomate status) after completing courses and passing an exam. It’s not required, but it signals competence and can help with malpractice insurance, credentialing, and patient trust.

PMHNP Scope: Where the Lines Get Blurry

Psychiatric Nurse Practitioners face different scope restrictions than psychiatrists. An NP’s scope of practice is defined by their training, certification, and state nursing board regulations — not just by holding a license.

A PMHNP is certified to treat psychiatric and mental health conditions. Prescribing for obesity — a metabolic/endocrine disorder — is arguably outside the usual PMHNP scope, even though technically a PMHNP can prescribe many of the same medications a psychiatrist can.

State nursing boards expect NPs to practice within their education and certification. If a PMHNP starts running a weight-loss clinic prescribing GLP-1s, state boards might question whether that aligns with psychiatric training. It’s not explicitly illegal, but it’s a gray area that could trigger complaints or investigations if outcomes are poor.

How PMHNPs navigate this:

1. Physician collaboration/supervision (where required): In states like Texas, Florida (for non-autonomous NPs), Pennsylvania, all NPs need a collaborating or supervising physician. If a PMHNP wants to prescribe weight-loss meds, the collaboration agreement should explicitly include obesity treatment protocols, and ideally the collaborating MD should be a primary care doc or someone with obesity medicine expertise — not just another psychiatrist (because then you’re both outside your specialty).

2. Additional certification/training: Some PMHNPs complete obesity medicine training programs or obtain ABOM certification to strengthen their scope argument. Others limit weight-loss prescribing to psych-adjacent cases — like prescribing metformin or GLP-1s specifically to counteract weight gain from antipsychotics, which falls more clearly within mental health medication management.

3. Working within telehealth platforms: Platforms like Klarity Health that serve both psychiatric and weight-loss patients often have separate clinical pathways. A PMHNP on the platform would handle psychiatric consultations, while weight-loss patients get routed to family NPs, internists, or physicians trained in obesity medicine. This keeps everyone in their lane and reduces scope-of-practice risk.

States with full NP practice authority (California post-2026 under AB 890, Illinois for NPs with 4,000+ hours, etc.) allow NPs to practice independently without physician oversight — but the expectation to stay within your training and competence remains. An independently practicing PMHNP in California could theoretically open a weight-loss clinic, but if they lack obesity medicine training and a patient develops complications, the nursing board could argue they practiced outside their scope.

Bottom line for PMHNPs: Prescribing weight-loss meds isn’t illegal, but it’s higher-risk than sticking to mental health. If you go this route, get proper training, work under appropriate physician collaboration (even if not legally required), and document the hell out of everything to show you’re meeting standard of care.

State-Specific Telehealth Prescribing Rules: What You Need to Know

Beyond DEA and scope issues, each state has its own telehealth prescribing requirements. Here’s what matters for psychiatrists and PMHNPs doing weight-loss telehealth:

California

• Licensure: Must be licensed in California to treat CA patients (or hold a special registration for out-of-state telehealth providers, but that doesn’t allow controlled substance prescribing)
• Telehealth modality: Live video required for initial consultations; California allows some asynchronous care but not for new prescriptions
• Consent: Must obtain and document patient consent for telehealth (Business & Professions Code §2290.5) — usually handled in intake paperwork
• PDMP: Mandatory check of CURES database before prescribing any Schedule II–IV controlled substance (including phentermine) for the first time, then at least every 4 months for ongoing therapy
• E-prescribing: All prescriptions must be electronic (including controlled substances) as of 2022
• NP/PA rules: NPs operate under Standardized Procedures with physician oversight unless they qualify for independent practice under AB 890 (phased implementation through 2026). By 2026, experienced NPs can practice independently in their certified population focus — but a PMHNP would still need to justify obesity treatment as within their scope or seek additional credentials.
• No special obesity treatment rules beyond standard medical practice, but the Medical Board expects documentation of evaluation, patient education, and monitoring

Local note: California’s Medi-Cal will stop covering GLP-1 medications for weight loss in January 2026, framing them as ‘non-covered cosmetic treatments.’ This will push more patients toward cash-pay telehealth services. Expect higher demand for affordable programs and more competition from startups.

Texas

• Licensure: Texas medical license required (or nursing license for NPs)
• Telehealth standard: Valid patient relationship can be established via synchronous audio-video or store-and-forward with audio, as long as it meets standard of care (Texas Occupations Code §111.005). Questionnaire-only prescribing doesn’t cut it.
• No in-person requirement for prescribing (the 2017 telemedicine reform removed that)
• PDMP: Practitioners must check Texas PMP (AWARxE) before prescribing certain controlled substances (opioids, benzos, barbiturates, carisoprodol). Phentermine isn’t on the mandatory list, but best practice is to check anyway.
• NP/PA delegation: NPs and PAs must have a Prescriptive Authority Agreement with a Texas MD/DO to prescribe. The agreement must explicitly include weight-loss medications if the NP/PA will prescribe them. Texas NPs cannot prescribe Schedule II substances (except in hospital/hospice settings), but phentermine is Schedule IV, so it’s allowed under delegation.
• Follow-up requirements: Texas law requires telehealth providers to give patients follow-up instructions and, with patient consent, send a report to the patient’s PCP within 72 hours
• Corporate practice of medicine: Non-physicians can’t own medical practices in Texas — weight-loss clinics must be physician-owned or structured via compliant MSO models

Local note: Texas has high obesity rates and strong telehealth demand. Regulators have cracked down on some weight-loss clinics for improper advertising or sham supervision agreements, so make sure your collaboration/delegation is real and documented.

Florida

• Telehealth law: Allows telehealth without in-person exams for most services. Prohibits teleprescribing Schedule II controlled substances except for psychiatric treatment, inpatient care, hospice, nursing homes. Weight-loss meds (phentermine = Schedule IV) are allowed via telehealth.
• Obesity prescribing rules (64B8-9.012): Applies to all physicians prescribing weight-loss drugs:
• Document BMI ≥30 or ≥27 with comorbidities (or body fat >25% male / >30% female)
• Obtain written informed consent from patient
• Re-evaluate at least every 3 months while on medication
• Cannot prescribe certain drugs off-label for weight loss (e.g., SSRIs purely for appetite suppression are prohibited)
• Consumer protection: Florida’s Commercial Weight-Loss Practices Act requires weight-loss providers to give clients written price quotes, disclose program duration, and provide a copy of the state’s ‘Weight-Loss Consumer Bill of Rights’
• PDMP: Must check E-FORCSE before prescribing any controlled substance to patients ≥16 years old
• NP/PA: Florida APRNs can achieve autonomous practice for certain specialties after experience requirements (Family NPs can, Psych NPs still require physician collaboration as of 2025). Most NPs prescribing weight-loss meds need a supervising physician agreement.

Local note: Florida’s telehealth market is hot for weight-loss services, but the state is vigilant about pill mills. The quarterly follow-up rule and written consent requirements are strict — skipping them can result in Board discipline. Calibrate Health (a telehealth weight-loss company) actually petitioned Florida to update its rules in 2022 to explicitly allow telemedicine for obesity treatment, and the Board complied — but with tight standards.

New York

• Controlled substance in-person rule: As of May 2025, requires at least one in-person evaluation before prescribing any controlled substance via telehealth (10 NYCRR §80.63), with narrow exceptions (referral from another provider who saw patient in-person within 12 months, covering for colleague, emergency 5-day supply). This means no phentermine via telehealth to new patients unless you or a coordinating provider sees them physically.
• Non-controlled prescribing: No restrictions — GLP-1 agonists can be prescribed via telehealth with standard video evaluation
• PDMP (I-STOP): Mandatory check of PMP registry within 24 hours before prescribing any Schedule II–IV controlled substance, every time
• E-prescribing: All prescriptions must be electronic (EPCS required for controlled substances)
• NP independence: NPs can practice independently after 3,600 hours of supervised practice (as of 2015 NP Modernization Act), including prescribing. But a PMHNP treating obesity should still justify it as within scope or obtain additional training.

Local note: New York’s strict controlled-substance rule makes telehealth weight-loss prescribing challenging if you’re using phentermine. Many providers in NY either use only GLP-1s (not controlled) or establish hybrid models with at least one in-person visit. NYC has high demand for weight-loss services (Ozempic craze is real), but primary care docs are skeptical of online-only clinics — coordinate care and document thoroughly.

Pennsylvania

• No specific telehealth statute as of 2025 — state relies on professional board guidance
• Standard of care applies: Must conduct adequate evaluation (history, exam via video) to justify prescribing
• PDMP: Must check PA PDMP before first prescription of opioid or benzodiazepine, then every time for those classes. For other controlled substances (stimulants, phentermine), check before first prescription and as clinically indicated.
• NP/PA: NPs need Collaborative Agreement with physician to prescribe; no independent practice in PA yet. PAs similarly need supervising physician agreements.
• No obesity-specific state rules — follow standard medical practice (NIH guidelines, etc.)

Local note: Pennsylvania is telehealth-friendly in practice (Medicaid covers it, joined nurse licensure compact), but lack of explicit statute means providers should be conservative with documentation and compliance to avoid board scrutiny.

Illinois

• Telehealth law: Explicitly allows telehealth to establish patient relationship and prescribe (Illinois Telehealth Act, amended 2021). No in-person requirement.
• Full Practice Authority for NPs: Illinois allows experienced APRNs (4,000+ hours, additional training) to practice independently, including prescribing Schedule II–V controlled substances (with consultation plan for Schedule II opioids). PMHNPs with FPA could theoretically run weight-loss practices, but scope-of-practice considerations still apply.
• PDMP: Must check PMPnow before prescribing Schedule II narcotics (opioids); not legally required for other controlled substances, but recommended
• E-prescribing: All controlled substances must be e-prescribed (as of Jan 2023)
• No state obesity rules — standard practice applies

Local note: Illinois is progressive on telehealth and NP autonomy. Chicago has robust healthcare infrastructure, but telehealth can reach underserved rural areas downstate. Illinois Medicaid started covering prescription weight-loss meds in 2024, which may increase demand.

The Economics: Why Platforms Like Klarity Make Sense

Here’s the part nobody talks about honestly: acquiring psychiatric or weight-loss patients independently is expensive and slow.

If you’re thinking ‘I’ll just run Google Ads or rank on Psychology Today and build a telehealth cash-pay weight-loss practice’ — reality check:

Real patient acquisition costs for mental health/weight loss:

• Google Ads: Mental health and weight-loss keywords cost $15–40+ per click. Conversion rates (click to booked appointment) are typically 2–5%. You’re realistically paying $200–400+ per booked patient after accounting for ad spend, click waste, and no-shows.
• SEO: Takes 6–12 months of consistent content, backlinks, and technical optimization before generating meaningful organic traffic. Most solo providers don’t have the expertise, patience, or $3,000–5,000/month budget to wait that long.
• Directory listings: Psychology Today, Zocdoc, etc., charge monthly subscription fees ($50–200/month) plus per-booking fees ($35–100+ on Zocdoc). You’re competing with hundreds of other providers on the same page. Total monthly cost adds up fast, and there’s no guarantee of patient volume.
• Hidden costs: Staff time to answer phone calls, qualify leads, schedule appointments. Many leads from cold advertising don’t convert — they ghost, don’t meet criteria, or price-shop. When you factor in opportunity cost, failed campaigns, and testing/optimization, DIY marketing rarely pencils out below $200–300 per acquired patient — and that’s if you’re good at it.

The Klarity model removes that risk entirely. Instead of spending $3,000–5,000/month on marketing with uncertain ROI, you pay a standard listing fee per new patient lead — only when a qualified patient books with you.

Here’s why that makes economic sense:

1. No upfront spend: Zero monthly subscription fees, no ad budget to burn through, no SEO retainer to pay before seeing results
2. Pre-qualified patients: Klarity’s intake process matches patients to your specialty and availability before they reach you — no time wasted on unqualified leads or no-shows
3. Guaranteed ROI: You only pay when you see a patient. If the patient doesn’t book or cancels, you don’t pay. Every dollar spent = a patient in your schedule.
4. Built-in infrastructure: Telehealth platform, EHR, billing support, compliance tools included — no separate software subscriptions (typical telehealth stack costs $200–500/month alone)
5. Both insurance and cash-pay: Klarity handles insurance credentialing and billing for in-network patients, plus cash-pay options for patients without coverage or seeking privacy — diversified revenue stream

Example math: Say you want to see 20 new weight-loss patients per month via telehealth.

• DIY route: $3,500/month marketing spend (Google Ads + SEO + directory listings) = $175 per patient acquired, assuming 20 actually book (realistically, you’ll spend months ramping up, have months with 10 patients and months with 5, waste budget on failed campaigns). Plus $300/month in software (telehealth platform, EHR, e-prescribing, PDMP access). Real cost: $3,800/month with unpredictable volume.

• Klarity route: Pay per patient booked at whatever the platform’s listing fee is (typically competitive with or better than your blended CAC from marketing), zero fixed costs. If you only see 10 patients one month, you only pay for 10. Scale to 30 next month, pay for 30. Completely variable, zero waste.

This isn’t theoretical. Providers who’ve tried to scale telehealth independently hit the same wall: marketing costs spiral, patient flow is inconsistent, and you end up spending 20 hours/week on business operations instead of clinical work.

Platforms solve the patient acquisition problem and let you focus on what you’re trained to do — practice medicine. For psychiatrists or PMHNPs expanding into weight loss, or joining as psych providers, Klarity’s infrastructure handles compliance (state-specific protocols, PDMP integration, consent workflows), marketing, and patient matching.

You control your schedule, choose your patient volume, and get paid per appointment — no gambling on marketing channels, no $5,000/month overhead hoping SEO eventually works.

Compliance Checklist: How to Prescribe Weight-Loss Meds Safely via Telehealth

If you’re adding weight management to your practice (or joining a platform that offers it), here’s what compliance actually looks like:

1. Verify licensure in patient’s state

• Must be licensed where patient is physically located at time of care
• Multi-state practice requires multiple licenses (or Interstate Medical Licensure Compact participation)

2. Use appropriate telehealth modality

• Live video required for initial evaluations in most states
• Audio-only insufficient for new prescriptions (some states allow for mental health follow-ups, not obesity treatment)
• Document patient consent for telehealth (required in California, Illinois, others; best practice everywhere)

3. Conduct proper evaluation

• Document weight, height, BMI (patient can self-report with visual verification via video)
• Review medical history: comorbidities (diabetes, hypertension, dyslipidemia), contraindications (pregnancy, active gallbladder disease for GLP-1s, uncontrolled hypertension for phentermine)
• Rule out secondary causes of obesity if indicated (thyroid dysfunction, Cushing’s)
• Assess for eating disorders, depression, other psych factors (this is where psychiatrists have natural advantage)
• Document previous weight loss attempts (diet, exercise, prior medications)

4. Obtain informed consent

• Discuss medication risks, benefits, alternatives
• Set realistic expectations (1–2 lbs/week weight loss is typical, not 20 lbs/month)
• Florida: Written informed consent required by regulation
• All states: Document the conversation in chart

5. Prescribe appropriately

• Start with lowest effective dose, titrate up per FDA labeling
• For GLP-1s: Follow manufacturer dose escalation schedules (e.g., semaglutide 0.25mg weekly x 4 weeks, then 0.5mg, etc.)
• For phentermine: Usually start 15mg or 37.5mg daily, reassess after 4 weeks
• Check PDMP for controlled substances (phentermine, Qsymia) — required in most states before first prescription, ongoing in some

6. Provide lifestyle counseling

• Diet and exercise recommendations (refer to dietitian if needed)
• Behavioral modification strategies
• Some states (New Jersey, Virginia) explicitly require documented nutrition counseling

7. Schedule follow-ups

• Florida: At least every 3 months while on medication (by regulation)
• Best practice: Monthly for first 3 months (to monitor titration, side effects), then quarterly
• Address side effects, assess efficacy, check blood pressure and metabolic markers

8. Coordinate care

• Inform patient’s PCP (with patient consent)
• Texas: Must send report to PCP within 72 hours of telehealth encounter (if patient consents)
• Refer to specialists as needed (cardiology for hypertension, endocrinology for diabetes management alongside GLP-1s)

9. Document everything

• Chart must show evaluation met standard of care
• Include BMI calculation, comorbidities, consent discussion, PDMP check (for controlled substances), medication education, lifestyle counseling, follow-up plan
• State medical boards review telehealth charts — documentation needs to be as thorough as in-person visits

10. Stay current on regulations

• DEA rules will change post-2026 — monitor federal register and professional association alerts
• State telehealth laws evolve (New York just amended rules in May 2025; other states update quarterly)
• Subscribe to state medical board newsletters, join professional societies (ATA, ASBP) for regulatory updates

FAQs

Can psychiatrists legally prescribe GLP-1 medications like Ozempic or Wegovy for weight loss?

Yes. Psychiatrists (MD/DO) have unrestricted prescribing authority and can prescribe FDA-approved weight-loss medications including GLP-1 agonists (semaglutide, tirzepatide, liraglutide). These drugs are not controlled substances, so no DEA restrictions apply. You must practice within the standard of care — conduct proper evaluation, obtain informed consent, monitor patients appropriately — same as any physician treating obesity. Some states like Florida have specific obesity treatment rules (quarterly follow-ups, written consent) that apply to all prescribers regardless of specialty.

Do I need an in-person visit to prescribe phentermine via telehealth?

Depends on the state. Federally, the DEA has extended telehealth flexibilities through December 31, 2026, allowing controlled substance prescribing (including phentermine, a Schedule IV appetite suppressant) without an in-person exam. However, New York state requires at least one in-person medical evaluation before prescribing any controlled substance via telehealth, with narrow exceptions. Most other states (California, Texas, Florida, Pennsylvania, Illinois) currently allow phentermine prescribing via telehealth under the federal extension. Always check current state medical board rules and verify patient location at each visit.

Can PMHNPs prescribe weight-loss medications, or is that outside their scope?

PMHNPs are trained and certified to treat psychiatric and mental health conditions. Prescribing purely for obesity (a metabolic disorder) is a gray area — not explicitly illegal, but potentially outside the typical PMHNP scope depending on state nursing board interpretation. Many PMHNPs handle this by: (1) prescribing weight-loss meds in the context of psychiatric care (e.g., metformin or GLP-1s to counteract antipsychotic-induced weight gain), (2) working under physician collaboration with a primary care or obesity medicine specialist, or (3) obtaining additional training/certification in obesity medicine. In states requiring physician oversight for NPs (Texas, Florida for non-autonomous NPs), the collaboration agreement should explicitly include weight-loss treatment if the PMHNP will prescribe for obesity.

What are the PDMP requirements for prescribing weight-loss medications?

Prescription Drug Monitoring Programs (PDMPs) track controlled substances. You must check your state’s PDMP before prescribing phentermine or other controlled weight-loss drugs. Requirements vary:

• California: Check CURES database before first Schedule II–IV prescription, then at least every 4 months for ongoing therapy
• Texas: Check Texas PMP before prescribing designated controlled substances (opioids, benzos, barbiturates, carisoprodol); phentermine not on mandatory list but best practice is to check
• Florida: Check E-FORCSE before prescribing any controlled substance to patients ≥16 years old
• New York: Check PMP within 24 hours before prescribing any Schedule II–IV controlled substance, every time
• Pennsylvania: Check before first opioid/benzo prescription, then each time for those classes; recommended for other controlled substances

GLP-1 medications (semaglutide, tirzepatide) are not controlled substances, so PDMP checks are not required — though some clinics check anyway as part of comprehensive patient history.

How do Florida’s obesity prescribing rules work for telehealth providers?

Florida regulation 64B8-9.012 sets specific standards for prescribing weight-loss medications that apply to all physicians (including via telehealth):

• Patient must have BMI ≥30 or ≥27 with comorbidities (or body fat >25% male / >30% female)
• Conduct initial evaluation (history, physical exam via video, necessary labs)
• Obtain written informed consent from patient outlining medication risks
• Re-evaluate patient at least every 3 months while on medication
• Cannot prescribe certain drugs off-label for weight loss (e.g., SSRIs purely for appetite suppression)

Florida’s Commercial Weight-Loss Practices Act also requires weight-loss providers to give written price quotes and a copy of the state’s ‘Weight-Loss Consumer Bill of Rights.’ Telehealth is explicitly allowed for obesity treatment in Florida as long as these standards are met.

What happens to telehealth prescribing after the DEA extension expires in 2026?

Unknown. DEA proposed rules in January 2025 to create permanent pathways for telemedicine prescribing of controlled substances (a ‘Special Registration’ for Schedule III–V, potential limited allowances for Schedule II), but these aren’t finalized. The temporary extension runs through December 31, 2026 to prevent disruption while permanent rules are developed. After 2026, we could see: (1) return to pre-COVID Ryan Haight rules requiring in-person exams, (2) permanent telemedicine flexibility with new registration requirements, or (3) specialty-specific allowances (e.g., psychiatrists

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated